Big Law

Gilead, U.S. Set to Square Off in Billion-Dollar Patent Trial Over HIV Drug

Gilead Sciences Inc is headed to trial in Delaware federal court this week to fight claims that it owes the U.S. government a share of multibillion-dollar profits from its HIV-prevention drug regimen.

The government is seeking more than $1 billion from Gilead for allegedly failing to compensate the Centers for Disease Control and Prevention (CDC) for discovering that Gilead’s HIV-treatment drug Truvada could help prevent the disease.

Jury selection starts on Tuesday in the case, which marks one of the first times the U.S. government has sued a drug maker to enforce its patent rights.

Read the source article at finance.yahoo.com

Back to top button